...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Allergy >Vitamin D as an adjunct to subcutaneous allergen immunotherapy in asthmatic children sensitized to house dust mite
【24h】

Vitamin D as an adjunct to subcutaneous allergen immunotherapy in asthmatic children sensitized to house dust mite

机译：维生素D可辅助对尘螨过敏的哮喘儿童进行皮下过敏原免疫治疗

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background We aimed to investigate the efficacy, safety, and T regulatory cell response of vitamin D as an adjunct to allergen-specific immunotherapy (IT). Methods Fifty children with asthma and receiving pharmacotherapy were randomized into three groups as: subcutaneous IT (SCIT) along with vitamin D supplementation (650 U/day; n: 17), SCIT alone (n: 15), and pharmacotherapy alone (n: 18). All patients were evaluated at baseline, 6th and 12th months for scorings of symptoms and medication, skin prick testing, total IgE, specific IgE, and Der p 1-specific IgG4. In addition, D. pteronyssinus-induced CD4 +CD25+FOXP3+T regulatory cell percentage, intracellular Foxp3 expression, and peripheral blood mononuclear cell IL-10 and TGF-β responses were assessed. Results In the SCIT + vitamin D and SCIT alone groups, total asthma symptom score (TASS), total symptom score (TSS), and total medication scores (TMS) were significantly lower than pharmacotherapy group at the end of 1 year. While the comparison of delta values (Δ 6th and Δ 12th month - baseline) of those scores revealed no significant differences between the two IT groups, TASS at the 6th month was lower in the SCIT + vitamin D group compared with others. There was a significant and positive trend in the levels of Der p 1-specific IgG4 in both IT groups throughout the study period. Whereas the levels of Der p 1-induced IL-10 and TGF-β were similar between IT groups, the mean fluorescence intensity of Foxp3 was highest in the SCIT + vitamin D group compared with others at the 12th month. The rate of discontinuation of inhaled corticosteroid (ICS) was 6/17 in SCIT + vitamin D, 3/15 in SCIT, and 0/18 in the pharmacotherapy group (P = 0.02). Conclusion Both SCIT groups fared better than pharmacotherapy alone at the end of 1 year. Although the clinical and immunologic outcomes were mostly similar between the two IT groups, some favorable outcomes of vitamin D warrant further investigation in more selected populations with varying doses as adjunct to IT.
机译：背景我们旨在研究维生素D作为变应原特异性免疫疗法（IT）的辅助剂的功效，安全性和T调节性细胞应答。方法将50例接受药物治疗的哮喘儿童随机分为三组：皮下IT（SCIT）联合维生素D补充剂（650 U /天; n：17）;单独的SCIT（n：15）和单独的药物治疗（n： 18）。在基线，第6和第12个月对所有患者进行症状和药物评分，皮肤点刺试验，总IgE，特异性IgE和Der p 1特异性IgG4评估。此外，评估了蕨类植物引起的CD4 + CD25 + FOXP3 + T调节细胞百分比，细胞内Foxp3表达以及外周血单核细胞IL-10和TGF-β反应。结果在单独的SCIT +维生素D和SCIT组中，总哮喘症状评分（TASS），总症状评分（TSS）和总药物评分（TMS）在1年末显着低于药物治疗组。比较这些分数的增量值（第6个月和第12个月的Δ-基线）表明，两个IT组之间没有显着差异，但SCIT +维生素D组的第6个月的TASS低于其他组。在整个研究期间，两个IT组的Der p 1特异性IgG4含量都有明显且积极的趋势。 IT组之间Der p 1诱导的IL-10和TGF-β的水平相似，而SCIT +维生素D组的Foxp3的平均荧光强度在第12个月时最高。 SCIT +维生素D的吸入皮质类固醇（ICS）停用率是6/17，SCIT是3/15，药物治疗组是0/18（P = 0.02）。结论在1年末，两个SCIT组的疗效均优于单独的药物治疗。尽管两个IT组之间的临床和免疫学结果大部分相似，但维生素D的一些有利结果仍需要在更多选择的人群中进行进一步研究，这些人群具有不同剂量的IT辅助剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号